Hemodynamic effect of dobutamine in patients with severe heart failure

Insights

Dobutamine significantly improved cardiac output in patients with severe congestive heart failure. This potent inotropic drug showed limited effects on heart rate and blood pressure, suggesting its therapeutic potential.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Severe congestive heart failure (CHF) is characterized by impaired cardiac function.
  • Low cardiac output is a critical determinant of prognosis in CHF.

Purpose of the Study:

  • To evaluate the efficacy and safety of dobutamine in patients with severe congestive heart failure.
  • To assess the effects of dobutamine on cardiac output, hemodynamics, and heart rate.

Main Methods:

  • Dobutamine was infused at 10 mug/kg per min in 15 patients with severe CHF.
  • Hemodynamic parameters including cardiac output, mean arterial pressure, heart rate, and pulmonary wedge pressure were monitored.
  • A lower dose (5 mug/kg per min) was also tested in a subset of patients.

Main Results:

  • Cardiac output increased significantly from 3.1 to 5.6 liters/min (P < 0.001).
  • Pulmonary wedge pressure decreased significantly from 27.4 to 21.1 mm Hg (P < 0.001).
  • Mean arterial pressure showed no significant change, and heart rate increased slightly (P < 0.02).
  • The 5 mug/kg per min dose also increased cardiac output, but to a lesser extent.

Conclusions:

  • Dobutamine is a potent inotropic agent with limited chronotropic and peripheral vascular effects.
  • It demonstrates significant efficacy in improving cardiac output in severe CHF.
  • Dobutamine warrants further investigation for the short-term management of low output heart failure.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...